Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
– Company to host live webcast and conference call Monday, December 15,…
Latest Data of InnoCares Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 08, 2025 21:04 ET | Source: InnoCare Pharma BEIJING, Dec. 08,…
Servier’s Voranigo (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and…
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results…
InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE:…
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 21, 2025 16:06 ET | Source: Supernus Pharmaceuticals, Inc. ROCKVILLE, Md.,…
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
November 10, 2025 21:56 ET | Source: Vor Biopharma BOSTON, Nov. 10,…
Edesa Biotech Announces Upcoming Conference Schedule
TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a…
Total Investment of Approx. USD 11.6 Million in TB and NTD R&D Projects With Partners Including Fujifilm, Stop TB Partnership, and the Ohio State University
TOKYO, Oct. 29, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced…
Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes
LEHI, Utah, Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical…